| Accession | SAMC1676562 |
|---|---|
| Accession in Other Database | GSA-Human: HRS285559 |
| Sample name | Sample106 |
| Title | Panel sequencing of P020_6 |
| Sample type | Human sample |
| Organism | Homo sapiens |
| Description | Targeted sequencing of tumor samples of P020_6 |
| Attributes | *This sample record contains additional controlled-access information that is avaiable from GSA-Human by requesting study HRA001346 in the GSA-Human system. |
| Release date | 2021-09-23 |
| BioProject Accession | PRJCA005206 |
| Submitter | xian zhang (guowei@cicams.ac.cn) |
| Organization | Geneseeq Technology Inc. |
| Submission date | 2023-06-18 |
| Resource name | Description |
|---|---|
| GSA-Human (1) | - |
| HRA001346 (Controlled Access) | Accurately evaluating minimal residual disease (MRD) could facilitate early intervention and personalized adjuvant therapies. Here, using ultradeep targeted next-generation sequencing (NGS), we evaluated the clinical utility of circulating tumor DNA (ctDNA) for dynamic recurrence risk and adjuvant chemotherapy (ACT) benefit prediction in resected non-small cell lung cancer (NSCLC). |